Health information now captured by what you wear
Putting patients increasingly in control of their well-being and health care outcomes has truly come of age.
Latest
AstraZeneca buys Takeda respiratory business
AstraZeneca plans to acquire the core respiratory business of Takeda Pharmaceutical Co. Ltd. for $575 million. Under the agreement, approximately 200 Takeda staff will transfer to AstraZeneca after the closing of the transaction, expected in the first quarter of 2016.
Rite Aid 3Q earnings meet Wall Street’s forecast
Rite Aid Corp. posted fiscal 2016 third-quarter adjusted earnings in line with Wall Street estimates and announced a special shareholders meeting to vote on its $17.2 billion deal to be acquired by Walgreens Boots Alliance Inc. Rite Aid said Thursday that for the third quarter ended Nov.
Former House Speaker Boehner to keynote NACDS Annual Meeting
John Boehner, the former Speaker of the U.S. House of Representatives, will deliver the keynote address at the 2016 NACDS Annual Meeting. The National Association of Chain Drug Stores said that Boehner (R.
Sucampo CEO to become chairman
Peter Greenleaf, chief executive officer of Sucampo Pharmaceuticals Inc., has been appointed as chairman of the board. Sucampo said late Tuesday that Greenleaf, the company’s CEO and a board member since March 2014, is slated to take the reins as chairman on Jan. 1.
General Mills makes strides in reducing sodium
General Mills reports that it’s making headway in its effort sodium by 20% across 10 key U.S. retail product categories by the end of this year. The food company said Tuesday that it has met or exceeded its goal in seven of 10 categories, with reductions across the 10 categories ranging from 18%
Rite Aid deploys EQuIPP Rx performance platform chainwide
Pharmacists in Rite Aid Corp.’s nearly 4,600 drug stores are now using the EQuIPP pharmacy performance measurement platform from Pharmacy Quality Solutions (PQS). Rite Aid said Wednesday that it’s the largest drug chain to enable EQuIPP access to all of its pharmacists.
CVS closes purchase of Target pharmacies, clinics
CVS Health has completed its $1.9 billion acquisition of Target Corp.’s pharmacy and retail health clinic business. The companies said Wednesday that Target’s 1,672 pharmacies in 47 states will be branded as CVS/pharmacy and operated under a store-within-a-store format.
CVS Health’s Merlo: ‘No one is better positioned’
At its annual Analyst Day event here, CVS Health updated its earnings guidance for 2016 and reiterated its five-year targets.
Mexican Rx market offers strong growth opportunities
one with outstanding growth potential for pharmacies that build strong differentiating capabilities. The Mexican pharmaceutical market grew 3% annually over the past few years to reach $14
Sanofi, Boehringer Ingelheim mull business swap
Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.
Hershey tabs Coke exec as global sales chief
The Hershey Co. has hired sales veteran Rob Gehring as global chief sales officer. Hershey said Gehring is slated to assume the post effective Jan. 18. He comes to the company from Coca-Cola North America, where he served as president of the Walmart global team since 2011.
Allergan rolls out IBS drug Viberzi
Allergan plc has released Viberzi (eluxadoline), a treatment for irritable bowel syndrome with diarrhea (IBS-D), to U.S. pharmacies. The company said Monday that Viberzi, a twice-daily oral medication, relieves the core symptoms of IBS-D: recurrent diarrhea and abdominal pain.
Walgreens, Valeant plan direct distribution model
Valeant Pharmaceuticals International Inc. and Walgreens have entered agreements in which the drug maker will directly distribute branded prescription drugs in a range of therapeutical areas to the pharmacy chain at reduced pricing.
Endo granted extended U.S. rights for Voltaren Gel
Endo International plc has received an extension of its exclusive U.S. marketing rights for Voltaren Gel (diclofenac sodium topical gel 1%), a nonsteriodal anti-inflammatory drug (NSAID). Endo said Monday that it also was granted extended U.S.
Newell Rubbermaid Acquires Jarden
Newell Rubbermaid Inc. is buying Jarden Corp. for about $13.2 billion in cash and stock, combining brands including Paper Mate, Sunbeam and Yankee Candle. Jarden shareholders will receive, per share, $21 and 0.862 shares of Newell Rubbermaid stock at closing.